Potential usefulness of inflammatory markers to monitor respiratory functional impairment in sarcoidosis.
BACKGROUND
Sarcoidosis is a multiorgan inflammatory granulomatous disorder of unknown origin for which adequate markers to monitor disease severity are lacking. The aim of this study was to evaluate the potential clinical usefulness of serologic markers of inflammation [high-sensitivity C-reactive protein (hs-CRP) and serum amyloid A (SAA)], T-cell activation [soluble interleukin-2 receptor (sIL2R)], and granuloma formation [angiotensin-converting enzyme (ACE)] for monitoring of sarcoidosis.


METHODS
Of the 185 sarcoidosis patients who visited the Sarcoidosis Management Center between 1999 and 2002, we selected 144 nonsmoking patients: 73 untreated (group I) and 71 treated (group II). Subgroups of the untreated patients [group Ia (nonchronic group with time since diagnosis < or = 2 years) and group Ib (chronic group with time since diagnosis >2 years)] were evaluated separately. ROC curves and logistic regression analyses were used to compare the diagnostic accuracy of different markers to assess disease severity. Pulmonary disease severity was defined by lung function test results.


RESULTS
In untreated subgroup Ia and the total untreated group (group I), sIL2R had the largest areas under the curves (AUCs; 0.891 and 0.799, respectively) and the highest sensitivity (82% and 64%), specificity (94% and 88%), and positive (82% and 70%) and negative (94% and 88%) predictive values among the evaluated markers in both untreated groups. Nevertheless, the confidence intervals for sIL2R AUC, sensitivity, and specificity were broad and partly overlapped those of ACE, hs-CRP, and SAA. In the treated group (group II), all four markers appeared to have comparable AUCs, ranging from 0.645 for SAA to 0.711 for sIL2R.


CONCLUSIONS
sIL2R appears to be useful for monitoring respiratory disease severity in sarcoidosis. We recommend sIL2R measurement in the follow-up of patients with sarcoidosis.
Rothkrantz-Kos
Snjezana
S
Department of Clinical Chemistry, Sarcoidosis Management Center, University Hospital Maastricht, and Nutrition and Toxicology Research Institute Maastricht (NUTRIM), University Maastricht, The Netherlands.
van Dieijen-Visser
Marja P
MP
Mulder
Paul G H
PG
Drent
Marjolein
M
D000328:Adult; D015415:Biomarkers / Q000097:blood; D002097:C-Reactive Protein / Q000032:analysis*; D003124:Colorimetry; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D007249:Inflammation / Q000097:blood / Q000175:diagnosis; D008163:Luminescent Measurements; D008297:Male; D009391:Nephelometry and Turbidimetry; D012372:ROC Curve; D015375:Receptors, Interleukin-2 / Q000097:blood*; D012044:Regression Analysis; D012129:Respiratory Function Tests; D017565:Sarcoidosis, Pulmonary / Q000097:blood / Q000175:diagnosis* / Q000503:physiopathology; D000685:Serum Amyloid A Protein / Q000032:analysis*; D012720:Severity of Illness Index; D012995:Solubility
D015415:Biomarkers; D015375:Receptors, Interleukin-2; D000685:Serum Amyloid A Protein; D002097:C-Reactive Protein